TO DETERMINE THE CLINICAL OUTCOMES IN DECEASED DONOR/LIVE RENAL TRANSPLANT RECIPIENTS WHO WERE CHANGED FROM MYCOPHENOLATE MOFETIL(MMF) TO AZATHIOPRINE(AZA) BASED TRIPLE IMMUNOSUPPRESSION.